Back to Resource Hub Case Study

Streamlining COVID Clinical Trials with Unified Technology

When conducting clinical trials during a pandemic, every moment counts. This case study showcases how we helped an emerging biopharmaceutical company execute a Phase II COVID treatment trial for critically ill patients with remarkable efficiency and minimal burden.

By implementing our SmartSignals® Unified Platform, we addressed three critical challenges: reducing cross-contamination risks from paper documentation, streamlining the consent process for patients and legally authorized representatives, and simplifying the site experience when using multiple eClinical solutions.

Our solution delivered a truly unified approach with direct data capture at the bedside, paperless electronic consent for both patients and remote caregivers, and a single access point with streamlined workflows that dramatically reduced training requirements and user burden.

The result? Implementation two weeks ahead of schedule while fully addressing all study requirements - proving that when technology works seamlessly in the background, researchers can focus on what matters most: generating quality evidence to advance patient care.

Similar posts

Looking for more insights? Explore related resources.

WHITE PAPER

Meeting the Needs of Study Participants During the COVID-19 Pandemic

READ THE PAPER
WHITE PAPER

Guidance for Implementing a Remote Assessment Strategy as a Protocol Adaptation During the COVID-19 Pandemic

READ THE PAPER
CASE STUDY

COVID-19 Vaccine Research Achieves Successful Outcomes with Support from Signant

READ THE STUDY

Get notified on new marketing insights

Here mention the benefits of subscribing